We are international
Donate
TEXT SIZE   


Myeloma Minute Special Edition: NEW DRUG COMBINATION - VELCADE® PLUS DOXIL® - APPROVED FOR MYELOMA
Combination Provides 43% Improvement in Time to Disease Progression
05.21.07
The International Myeloma Foundation
MYELOMA MINUTE SPECIAL EDITION
NEW DRUG COMBINATION - VELCADE� PLUS DOXIL� -
APPROVED FOR MYELOMA


Combination Provides 43% Improvement in Time to Disease Progression

The U.S. Food and Drug Administration has approved a new treatment option for myeloma patients who have relapsed or who have not responded to at least one other course of treatments. The combination of DOXIL� with VELCADE� provides nearly a three month improvement in time to disease progression as compared to VELCADE alone, which is a 43% improvement in response according to a phase III multi-national clinical trial.

"This is an important new combination for patients, especially those with resistant myeloma, because of the VELCADE/DOXIL synergy � VELCADE increases the sensitivity of cancer cells to DOXIL and DOXIL does the same for VELCADE," said Brian G.M. Durie, M.D., chairman and co-founder of the IMF. "The growing success treating myeloma and extending patients' lives is due in large part to new drugs that can be used in combination and in sequence, and the approval of the new VELCADE/DOXIL combination fits perfectly into that strategy."

DOXIL is a specially (liposomal) formulated version of the chemotherapy agent doxorubicin, and is approved for use in other forms of cancer. VELCADE, bortezomib, is approved for myeloma patients who have relapsed or not responded to a previous course of treatment. VELCADE/DOXIL may be used with or without steroids providing patients with a steroid-free alternative.


View Back Issues Online...
New to the IMF Myeloma Minute? See what you've been missing by viewing previous issues online!

To unsubscribe from the Myeloma Minute, click here

If a friend forwarded this Minute to you, why not get your own subscription? It's free. Click here to subscribe.

Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here.

Many thanks to the supporters of The Myeloma Minute:
Celgene Corporation, Kyphon, Millennium Pharmaceuticals, Ortho Biotech, and The Binding Site.
Please call the hotline (800) 452-CURE (800-452-2873) or email TheIMF@myeloma.org if you have any questions.
Copyright 2002-2007. International Myeloma Foundation. All Rights Reserved.


 related articles